NEW YORK, NY--(Marketwire - Aug 2, 2012) - Alliqua, Inc. (OTCBB: ALQA) ("Alliqua" or the "Company"), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the Company has named Stephen A. Brigido, D.P.M. to serve as chairman for the Alliqua Scientific Advisory Board ("SAB").

Dr. Brigido brings a wealth of experience to the team at Alliqua. He is a leading board certified Foot and Ankle surgeon for Coordinated Health, a physician owned hospital network serving eastern Pennsylvania, where he also serves as Chairman of the Institutional Review Board and Director of the Fellowship for Foot and Ankle Surgery. Dr. Brigido is a fellow of the American College of Foot and Ankle Surgeons as well as a Diplomate of the American Board of Podiatric Surgery.

As an active academician and researcher, focusing on the areas of acellular regenerative tissue scaffolds and foot and ankle reconstruction, Dr. Brigido has numerous publications that can be found in journals such as Techniques in Foot and Ankle Surgery and Foot and Ankle Specialist. He has also published research regarding lower extremity wound treatments in journals such as International Wound Journal and Advances in Skin and Wound Care. Additionally, Dr. Brigido has been instrumental in the development of products for the treatment of diabetic ulcers and hardware systems used in ankle and foot surgeries. Dr. Brigido graduated from Randolph-Macon College with a B.S. in Biology and received his Doctor of Podiatric Medicine from Temple University. 

Commenting on his new role at Alliqua, Dr. Brigido stated, "I am honored and excited to assume the role of chairman of the SAB at Alliqua, and to have the opportunity to work with such a dynamic and innovative company. Having had direct experience with Alliqua's SilverSeal®, silver based, hydrogel wound dressings, I believe this application, along with Alliqua's technology platform, has tremendous commercial potential in the areas of wound care and the transdermal delivery of a wide array of drugs. I look forward to working with the scientific and business team at Alliqua to help drive the development of Alliqua's products and deliver on this company's vast potential to help patients suffering from lower extremity wounds."

Commenting on Dr. Brigido's addition, Richard Rosenblum, President of Alliqua, stated, "As part of our corporate growth, it is important to surround ourselves with top talent in those areas where we are focusing our development and marketing efforts. As a surgeon and researcher, Dr. Brigido is keenly aware of the demands on wound care products and the role for transdermal applications for drug delivery. His experience as well as his professional reputation will be invaluable to us as we further our SilverSeal® commercialization plans. Additionally, as chairman, we are confident that he will play an active role in helping to steer our future development plans and product road map to maximize our growth potential in the coming years."

About Alliqua, Inc.

Alliqua, Inc. (OTCBB: ALQA) ("Alliqua") is an advanced biopharmaceutical company focused on the development, manufacturing and distribution of our proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform, produces hydrogels, a three dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations. We currently market our new line of 510K FDA approved hydrogel products for wound care under our Silver Seal brand. Due to the electron beam production process at our 16,000 square foot GMP manufacturing facility, we can aggressively develop and custom manufacture a wide variety of hydrogels. Our hydrogels can be customized for various transdermal applications to address multi-billion dollar market opportunities in the treatment of wounds such as diabetic ulcers, as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries. By using our drug delivery platform in combination with certain drugs, pharmaceutical companies can increase patient compliance as well as potentially extend the life of valuable drug patents. For additional information, please visit www.alliqua.com. To receive future press releases via email, please visit: http://alliqua.com/index.php?page=investor-alerts.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.